General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
UCB Canada Inc.
Indication:
Epilepsy, partial-onset seizures
Last updated October 22, 2018
Status:
Concluded with an LOI
Manufacturer:
Raptor Pharmaceuticals Inc.
Indication:
Cystic fibrosis with chronic pulmonary Pseudomonas aeruginosa infections
Last updated October 11, 2018
Fibristal (ulipristal acetate)
Status:
Concluded without agreement
Manufacturer:
Allergan Inc.
Indication:
Uterine fibroids (signs and symptoms) - 2nd cycle pre-surgery
Last updated September 28, 2018
Status:
Concluded with an LOI
Manufacturer:
Biogen Canada Inc.
Indication:
Spinal Muscular Atrophy
Last updated September 26, 2018
Toujeo (insulin glargine injection)
Status:
Concluded with an LOI
Manufacturer:
Sanofi-Aventis Canada Inc.
Indication:
Diabetes Mellitus, Type 1 & 2
Last updated September 12, 2018
Synjardy (empagliflozin/metformin)
Status:
Concluded with an LOI
Manufacturer:
Boehringer Ingelheim (Canada) Ltd.
Indication:
Diabetes Mellitus, Type 2
Last updated September 11, 2018
Status:
Concluded with an LOI
Manufacturer:
Boehringer Ingelheim (Canada) Ltd.
Indication:
Diabetes Mellitus, Type 2 with high cardiovascular risk
Last updated September 11, 2018
Dysport Therapeutic (abobotulinumtoxina)
Status:
Concluded with an LOI
Manufacturer:
Ipsen Biopharmaceuticals Canada, Inc.
Indication:
Lower Limb Spasticity
Last updated August 30, 2018
Status:
Concluded with an LOI
Manufacturer:
Amicus Therapeutics
Indication:
Fabry Disease
Last updated August 28, 2018
Enstilar (calcipotriol/betamethasone)
Status:
Concluded with an LOI
Manufacturer:
LEO Pharma Inc.
Indication:
Psoriasis, moderate to severe plaque
Last updated August 27, 2018